German biotech firm Evotec (EVT: Xetra) and MaRS Innovation today announced the launch of Fibrocor Therapeutics, a Toronto, Canada-based company focused on developing first-in-class therapeutics targeting fibrotic diseases.
The company was launched with C$2.8 million (~$2.1 million) financing, which includes cash from MaRS Innovation, the commercialization agent for 15 of Ontario's leading academic institutions. Evotec will provide all drug discovery activities and will also receive an equity stake.
Fibrocor takes a new approach to understanding and treating fibrosis, bringing together clinical expertise and access to disease tissue with high-throughput molecular analysis infrastructure and expertise in clinically-predictive animal models of fibrosis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze